147 related articles for article (PubMed ID: 20953835)
1. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
Pérez-Tenorio G; Karlsson E; Waltersson MA; Olsson B; Holmlund B; Nordenskjöld B; Fornander T; Skoog L; Stål O
Breast Cancer Res Treat; 2011 Aug; 128(3):713-23. PubMed ID: 20953835
[TBL] [Abstract][Full Text] [Related]
2. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.
Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O
Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818
[TBL] [Abstract][Full Text] [Related]
3. Gene amplification of ribosomal protein S6 kinase-1 and -2 in gastric cancer.
Yoshida S; Matsumoto K; Arao T; Taniguchi H; Goto I; Hanafusa T; Nishio K; Yamada Y
Anticancer Res; 2013 Feb; 33(2):469-75. PubMed ID: 23393338
[TBL] [Abstract][Full Text] [Related]
4. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.
Bostner J; Karlsson E; Eding CB; Perez-Tenorio G; Franzén H; Konstantinell A; Fornander T; Nordenskjöld B; Stål O
Endocr Relat Cancer; 2015 Jun; 22(3):331-43. PubMed ID: 25972244
[TBL] [Abstract][Full Text] [Related]
5. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
Karlsson E; Pérez-Tenorio G; Amin R; Bostner J; Skoog L; Fornander T; Sgroi DC; Nordenskjöld B; Hallbeck AL; Stål O
Breast Cancer Res; 2013; 15(5):R96. PubMed ID: 24131622
[TBL] [Abstract][Full Text] [Related]
6. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.
Karlsson E; Magić I; Bostner J; Dyrager C; Lysholm F; Hallbeck AL; Stål O; Lundström P
PLoS One; 2015; 10(12):e0145013. PubMed ID: 26698305
[TBL] [Abstract][Full Text] [Related]
7. Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.
Sridharan S; Basu A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054043
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of S6K1 and S6K2 expression in endometrial adenocarcinomas.
Lyzogubov VV; Lytvyn DI; Dudchenko TM; Lubchenko NV; Pogrybniy PV; Nespryadko SV; Vinnitska AB; Usenko VS; Gout IT; Filonenko VV
Exp Oncol; 2004 Dec; 26(4):287-93. PubMed ID: 15627061
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors.
Filonenko VV; Tytarenko R; Azatjan SK; Savinska LO; Gaydar YA; Gout IT; Usenko VS; Lyzogubov VV
Exp Oncol; 2004 Dec; 26(4):294-9. PubMed ID: 15627062
[TBL] [Abstract][Full Text] [Related]
10. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors.
Savinska LO; Lyzogubov VV; Usenko VS; Ovcharenko GV; Gorbenko ON; Rodnin MV; Vudmaska MI; Pogribniy PV; Kyyamova RG; Panasyuk GG; Nemazanyy IO; Malets MS; Palchevskyy SS; Gout IT; Filonenko VV
Eksp Onkol; 2004 Mar; 26(1):24-30. PubMed ID: 15112576
[TBL] [Abstract][Full Text] [Related]
12. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer.
Kim EK; Kim HA; Koh JS; Kim MS; Kim KI; Lee JI; Moon NM; Ko E; Noh WC
Breast Cancer Res Treat; 2011 Feb; 126(1):93-9. PubMed ID: 21184268
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer.
Lyzogubov V; Khozhaenko Y; Usenko V; Antonjuk S; Ovcharenko G; Tikhonkova I; Filonenko V
Exp Oncol; 2005 Jun; 27(2):141-4. PubMed ID: 15995633
[TBL] [Abstract][Full Text] [Related]
16. Characterization of S6K2, a novel kinase homologous to S6K1.
Lee-Fruman KK; Kuo CJ; Lippincott J; Terada N; Blenis J
Oncogene; 1999 Sep; 18(36):5108-14. PubMed ID: 10490847
[TBL] [Abstract][Full Text] [Related]
17. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
18. Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR.
Rosner M; Hengstschläger M
Oncogene; 2011 Nov; 30(44):4509-22. PubMed ID: 21602892
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer.
Ma BL; Shan MH; Sun G; Ren GH; Dong C; Yao X; Zhou M
Mol Med Rep; 2015 Oct; 12(4):5246-54. PubMed ID: 26151180
[TBL] [Abstract][Full Text] [Related]
20. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G
Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
